Published in Syst Rev on February 15, 2017
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med (2009) 35.37
Contradicted and initially stronger effects in highly cited clinical research. JAMA (2005) 11.15
A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J (2011) 10.70
Meta-analysis of the literature or of individual patient data: is there a difference? Lancet (1993) 6.16
Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ (2010) 5.60
Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis. Ann Intern Med (2013) 4.60
Meta-analysis and the meta-epidemiology of clinical research. BMJ (1997) 4.07
Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures. JAMA (2009) 4.07
Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data. Ann Intern Med (2013) 4.02
To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data. Eval Health Prof (2002) 3.11
Meta-analysis under scrutiny. Lancet (1997) 2.96
Access to patient-level data from GlaxoSmithKline clinical trials. N Engl J Med (2013) 2.62
Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head. Stat Med (2002) 2.49
A comparison of meta-analytic results using literature vs individual patient data. Paternal cell immunization for recurrent miscarriage. JAMA (1995) 2.02
Why Science Is Not Necessarily Self-Correcting. Perspect Psychol Sci (2012) 1.86
Worldwide collaborative observational study and meta-analysis on allogenic leukocyte immunotherapy for recurrent spontaneous abortion. Recurrent Miscarriage Immunotherapy Trialists Group. Am J Reprod Immunol (1994) 1.84
Meta-analysis of continuous outcomes combining individual patient data and aggregate data. Stat Med (2008) 1.65
Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses. BMJ (2012) 1.58
Conflicting conclusions from two systematic reviews of epidural steroid injections for sciatica: which evidence should general practitioners heed? Br J Gen Pract (1999) 1.48
Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension (2005) 1.41
RhBMP-2 versus iliac crest bone graft for lumbar spine fusion: a randomized, controlled trial in patients over sixty years of age. Spine (Phila Pa 1976) (2008) 1.35
A model for dissemination and independent analysis of industry data. JAMA (2011) 1.35
Controversy of oral contraceptives and risk of rheumatoid arthritis: meta-analysis of conflicting studies and review of conflicting meta-analyses with special emphasis on analysis of heterogeneity. Am J Epidemiol (1996) 1.02
Meta-analysis of trials of recombinant human bone morphogenetic protein-2: what should spine surgeons and their patients do with this information? Ann Intern Med (2013) 0.99
Closing in on the truth about recombinant human bone morphogenetic protein-2: evidence synthesis, data sharing, peer review, and reproducible research. Ann Intern Med (2013) 0.89
Reproducibility of systematic literature reviews on food, nutrition, physical activity and endometrial cancer. Public Health Nutr (2007) 0.88
Detecting the effects of thromboprophylaxis: the case of the rogue reviews. BMJ (1997) 0.88
Commentary: Despite reports of catastrophic complications, why recombinant human bone morphogenetic protein-2 should be available for use in anterior cervical spine surgery. Spine J (2012) 0.81
Value of updating a systematic review in surgery using individual patient data. Br J Surg (2004) 0.79
Recombinant Human Bone Morphogenetic Protein-2 in Spine Surgery. JBJS Rev (2014) 0.77
Waste recombinant DNA: effectiveness of thermo-treatment to manage potential gene pollution. Environ Pollut (2009) 0.77
Systematic review of reduced therapy regimens for children with low risk febrile neutropenia. Support Care Cancer (2016) 0.77